Drugs / Dimenhydrinate
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | DIMENHYDRINATE | — | 1972-05-31 | fda.gov ↗ |
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT01543945 | Mar 2008 → Dec 2011 | — | Prince of Songkla University | Completed | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT06321341 | Jan 2024 → Dec 2026 expected | dysautonomia | Valenta Pharm JSC | Recruiting | No outcome recorded |
| Phase 4 | NCT00124787 | Apr 2005 → Feb 2012 | gastroenteritis | St. Justine's Hospital | Completed | No outcome recorded |
| Comparator or background therapy10 trials | ||||||
| Phase 2 | NCT01008007 Comparator | Sep 2009 → May 2010 | — | Catalysis SL | Completed | No outcome recorded |
| Phase 3 | NCT04606264 Comparator | May 2023 → Mar 2025 | — | Jennifer Holder-Murray | Completed | No outcome recorded |
| Phase 3 | NCT02112578 Comparator | Nov 2016 → Apr 2017 | peripheral vertigo | Apsen Farmaceutica S.A. | Completed | No outcome recorded |
| Phase 4 | NCT04835116 Background | Apr → Oct 2019 | — | Armed Forces Institute of Urology, Rawalpindi | Completed | No outcome recorded |
| Phase 4 | NCT01890538 Comparator | Jun 2013 → May 2014 | peripheral vertigo | Kocaeli University | Completed | No outcome recorded |
| Phase 4 | NCT02253524 Comparator | Nov 2012 → May 2013 | — | Pamukkale University | Completed | No outcome recorded |
| Phase 4 | NCT02382146 Comparator | Apr 2012 → Dec 2014 | — | Yeditepe University Hospital | Completed | No outcome recorded |
| — | NCT06395064 Comparator | May 2024 → Dec 2025 | female reproductive system neoplasm | Preeyaporn Jirakittidul | Unknown | No outcome recorded |
| — | NCT05590936 Comparator | Jan 2018 → Dec 2022 | — | University of Thessaly | Completed | No outcome recorded |
| — | NCT00791960 Comparator | Nov 2008 → Sep 2009 | — | Samuel Lunenfeld Research Institute, Mount Sinai Hospital | Completed | No outcome recorded |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 14 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Dimenhydrinate | “dexamethasone 8 mg intravenous dimenhydrinate 1mg/kg intravenous” NCT02382146 ↗12“intramuscular injection of one bulb of dimenhydrinate (50 mg)” NCT01008007 ↗ “Dimenhydrinate + Cinnarizine” NCT06321341 ↗ |
| Known as | Antemin | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200406 ↗ |
| Known as | Dimenhidrinato | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200406 ↗ |
| Known as | DMT | “It has been reported that the most commonly used medications for parenteral treatment of vertigo and nausea-vomiting in emergency department are dimenhydrinate (DMT) and...” NCT02253524 ↗ |
| Known as | Dramamine | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200406 ↗ |
| Known as | NSC-117855 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200406 ↗ |
| Known as | Vertigo-vomex s | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200406 ↗ |
| Action | Inhibit | “Dimenhydrinate, a histamine receptor blocker” NCT00124787 ↗1“Histamine H1 receptor antagonist” CHEMBL1200406 ↗ |
| Modality | Small molecule | “ethanolamine-derivative anti-histamine” NCT00124787 ↗ |
| Route | Oral | “Do children treated with oral dimenhydrinate during acute gastro-enteritis experience less vomiting episodes than children treated with placebo?” NCT00124787 ↗ |
| Target | HRH1 | “Histamine H1 receptor antagonist” CHEMBL1200406 ↗ |